On May 28, 2026 Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) reported that results from its Phase 1a trial evaluating LNP8701, a novel SOS1 inhibitor, have been accepted for publication at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2026 Annual Meeting, which is being held from May 29-June 2, 2026, in Chicago, IL. The abstract titled "A phase 1 study to evaluate safety, tolerability, and pharmacokinetics of LNP8701 (SOS1 inhibitor) in subjects with metastatic solid tumors" has been published in the Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology track and can be viewed on the ASCO (Free ASCO Whitepaper) website (View Source).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The abstract reports the findings from an ongoing first-in-human study of LNP8701 in patients with solid tumors. LNP8701 is an orally administered, investigational SOS1 (Son of Sevenless1) inhibitor, designed to block SOS1-mediated RAS activation, thereby limiting oncogenic signaling that promotes tumor growth. Results indicate that LNP8701 was well tolerated with desirable safety, pharmacokinetics profile and favorable anti-tumor activity. The preliminary efficacy findings demonstrate that two patients completed LNP8701 monotherapy for 12 cycles (i.e., 1 year) and one patient completed 14 cycles with stable disease.
Vinita Gupta, CEO, Lupin, said, "The findings from the ongoing Phase 1 study highlight the emerging potential of LNP8701 and signal progress in our pursuit of novel therapies for difficult-to-treat cancers. We are encouraged by this momentum and remain committed to transforming scientific discovery into meaningful patient outcomes."
Current data suggest that LNP8701 is safe and well-tolerated across all tested dosing levels. Lupin will continue to study the efficacy of LNP8701 in its phase 1b trial in India and explore its potential to treat solid tumors both as a monotherapy and as part of a combination.
Details of the Abstract:
Abstract Number: e15162
Track: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Citation: J Clin Oncol 44, 2026 (suppl 16; abstr e15162)
DOI: 10.1200/JCO.2026.44.16_suppl.e15162
Clinical Trial Registration Number: CTRI/2024/08/072373
Abstract link: View Source
(Press release, Lupin, MAY 28, 2026, View Source [SID1234666164])